Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Messina

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Headache|May 6, 2015
AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacksStewart J Tepper, Roger K Cady, Stephen Silberstein, et al.
Frontiers in Immunology|October 5, 2020
A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe DiseasePunita Gupta, Brian J Shayota, Ankit K Desai, et al.
International Forum of Allergy & Rhinology|August 26, 2024
EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trialsSarah K Wise, Nithin D Adappa, Rakesh K Chandra, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 20, 2024
Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controlled Trials (ReOpen1 and ReOpen2)James N Palmer, Nithin D Adappa, Rakesh K Chandra, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Headache|May 6, 2015
AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacksStewart J Tepper, Roger K Cady, Stephen Silberstein, et al.
Frontiers in Immunology|October 5, 2020
A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe DiseasePunita Gupta, Brian J Shayota, Ankit K Desai, et al.
International Forum of Allergy & Rhinology|August 26, 2024
EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trialsSarah K Wise, Nithin D Adappa, Rakesh K Chandra, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 20, 2024
Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controlled Trials (ReOpen1 and ReOpen2)James N Palmer, Nithin D Adappa, Rakesh K Chandra, et al.
Pageof 3